A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for (68)Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors

(68)Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumor (NET) detection and localization. However, the optimal peptide mass and radioactivity ranges for (68)Ga-satoreotide trizoxetan have not yet been esta...

Descripción completa

Detalles Bibliográficos
Autores principales: Virgolini, Irene, Bahri, Shadfar, Kjaer, Andreas, Grønbæk, Henning, Iversen, Peter, Carlsen, Esben A., Loft, Mathias, Knigge, Ulrich, Maffey-Steffan, Johanna, Powell, Christine, Miller, Colin G., Rohban, Thomas, McEwan, Sandy, Czernin, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2022
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978200/
https://www.ncbi.nlm.nih.gov/pubmed/34215673
http://dx.doi.org/10.2967/jnumed.121.261936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978200/
https://www.ncbi.nlm.nih.gov/pubmed/34215673
http://dx.doi.org/10.2967/jnumed.121.261936

Ejemplares similares